inclusion criteria: patient or guardian/health proxy must provide informed consent (and assent if applicable) before any study assessment is performed. male and female patients aged ≥ 12 years (or ≥ the lower age limit allowed by health authority and/or ethics committee/institutional review board approvals). patients with coronavirus (sars-cov-2) infection confirmed by polymerase chain reaction (pcr) test or another rapid test from the respiratory tract prior to randomization. patients currently hospitalized or will be hospitalized prior to randomization. patients, who meet at least one of the below criteria: * pulmonary infiltrates (chest x ray or chest ct scan); * respiratory frequency ≥ 30/min; * requiring supplemental oxygen; * oxygen saturation ≤ 94% on room air; * arterial oxygen partial pressure (pao2)/ fraction of inspired oxygen (fio2) \< 300mmhg (1mmhg=0.133kpa) (corrective formulation should be used for higher altitude regions (over 1000m).

inclusion criteria: patient or guardian/health proxy must provide informed consent (and assent if applicable) before any study assessment is performed. male and female patients aged ≥ 12 years (or ≥ the lower age limit allowed by health authority and/or ethics committee/institutional review board approvals). patients with coronavirus (sars-cov-2) infection confirmed by polymerase chain reaction (pcr) test or another rapid test from the respiratory tract prior to randomization. patients currently hospitalized or will be hospitalized prior to randomization. patients, who meet at least one of the below criteria: * pulmonary infiltrates (chest x ray or chest ct scan); * respiratory frequency ≥ 30/min; * requiring supplemental oxygen; * oxygen saturation ≤ 94% on room air; * arterial oxygen partial pressure (pao2)/ fraction of inspired oxygen (fio2) \< 300mmhg (1mmhg=0.133kpa) (corrective formulation should be used for higher altitude regions (over 1000m).

inclusion criteria: patient or guardian/health proxy must provide informed consent (and assent if applicable) before any study assessment is performed. male and female patients aged ≥ 12 years (or ≥ the lower age limit allowed by health authority and/or ethics committee/institutional review board approvals). patients with coronavirus (sars-cov-2) infection confirmed by polymerase chain reaction (pcr) test or another rapid test from the respiratory tract prior to randomization. patients currently hospitalized or will be hospitalized prior to randomization. patients, who meet at least one of the below criteria: - pulmonary infiltrates (chest x ray or chest ct scan); - respiratory frequency ≥ 30/min; - requiring supplemental oxygen; - oxygen saturation ≤ 94% on room air; - arterial oxygen partial pressure (pao2)/ fraction of inspired oxygen (fio2) < 300mmhg (1mmhg=0.133kpa) (corrective formulation should be used for higher altitude regions (over 1000m).

inclusion criteria: patient or guardian/health proxy must provide informed consent (and assent if applicable) before any study assessment is performed. male and female patients aged ≥ 12 years (or ≥ the lower age limit allowed by health authority and/or ethics committee/institutional review board approvals). patients with coronavirus (sars-cov-2) infection confirmed by polymerase chain reaction (pcr) test or another rapid test from the respiratory tract prior to randomization. patients currently hospitalized or will be hospitalized prior to randomization. patients, who meet at least one of the below criteria: - pulmonary infiltrates (chest x ray or chest ct scan); - respiratory frequency ≥ 30/min; - requiring supplemental oxygen; - oxygen saturation ≤ 94% on room air; - arterial oxygen partial pressure (pao2)/ fraction of inspired oxygen (fio2) < 300mmhg (1mmhg=0.133kpa) (corrective formulation should be used for higher altitude regions (over 1000m).